See also stories tagged with Drug discovery
La Trobe University scientists have uncovered the critical role fatty cell structures play in our body's early detection and defense against viruses. Published in Nature Communications, the discovery could open the door to ...
Drug development is among the slowest, most failure-prone processes in modern science, with about 90% of drug candidates never reaching the market. Today, artificial intelligence methods have accelerated the first step—plucking ...
Manchester's quantum researchers are building on the Ferranti Mark I legacy, using ultra-pure silicon and single atoms to move quantum computing closer to real-world impact.
As the world faces new and often untreatable viral threats, Simon Fraser University researchers have found a way to cut years off the time it takes to discover antiviral drugs. The new research enables scientists to quickly ...
Penn Engineers have developed PeptiVerse, an AI-powered platform that predicts key chemical and biological properties of peptides, strings of amino acids whose medical potential has been demonstrated by the success of GLP-1 ...
Some microorganisms that hold great promise for research have long lain dormant in historical collections. But only through new methods are their diversity and potential becoming apparent. The team led by Professor Christian ...
Bacteria have spent decades evolving resistance to virtually every antibiotic we have thrown at them. To stay ahead, new drugs must hit targets that existing antibiotics have never touched. A research team at the Helmholtz ...
African sleeping sickness and related diseases can be treated only with toxic and sometimes ineffective drugs. Now, University of Connecticut researchers show in Nucleic Acids Research that a crucial enzyme could be the key ...
Scientists at the Peter MacCallum Cancer Center have uncovered new insights into how cells regulate DNA methylation, a fundamental process that helps keep potentially harmful viral elements in our genome under control.
When researchers screen potential tuberculosis drugs, they often end up with too many options. Some look promising but later prove to be costly dead ends. "We might get thousands of compounds from a screen and then have to ...
